Table 2.
Median survival times of canine glioma treatment studies to date with treatment modalities and comparison with the results of our study.
| Study | Animals Number | Tumour | Diagnosis | Chemotherapy/Radiotherapy Treatment | Surgery | Median ST (Days) |
|---|---|---|---|---|---|---|
| Presumptive | ||||||
| Van Meervenne, S. et al. (2012) [31] | 56 dogs | Intra or extra-axial | Presumptive (CT) | Lomustine | No | 93 |
| Moirano, S. et al. (2018)32 | 40 dogs | Gliomas | Presumptive (MRI) | Lomustine | No | 138 |
| Magalhães, TR. et al. (2021) [35] | 16 dogs | Gliomas | Presumptive (MRI) | Radiotherapy | No | 512 |
| Dolera, M. et al. (2017) [17] | 22 dogs | Gliomas | Presumptive (MRI) | Radiotherapy | No | 383 |
| Dolera, M. et al. (2017) [17] | 20 dogs | Gliomas | Presumptive (MRI) | Radiotherapy and temozolomide | No | 420 |
| Moirano, S. et al. (2020) [16] | 5 dogs | Gliomas | Presumptive (MRI) | Radiotherapy and chemotherapy (lomustine, hydroxyurea, temozolomide or toceranib phosphate) | No | 636 |
| Necropsy | ||||||
| José-López, R. et al. (2021) [2] | 12 dogs | Gliomas | Definitive (MRI and necropsy) | Chemotherapy (lomustine, temozolomide, cytarabine and clinical trial drug) | No | 56 |
| Adams et al. (2005) [27] | 12 dogs | Gliomas | Definitive (MRI and necropsy) | Radiotherapy | No | 255 |
| José-López, R. et al. (2021) [2] | 1 dog | Glioma undefined (high-grade) | Definitive (MRI and necropsy) | Radiotherapy | No | 29 |
| Hasegawa, D. et al. (2012) [29] | 1 dog | Anaplastic Oligodendroglioma | Definitive (MRI and necropsy) | Radiotherapy and lomustine | No | 910 |
| Biopsy | ||||||
| Suñol, A. et al. (2017) [9] | 14 dogs | Gliomas (8 oligodendrogliomas, 4 astrocytomas, and 2 anaplastic gliomas) | Definitive (MRI and biopsy) | No | Yes | 66 |
| José-López, R. et al. (2021) [2] | 4 dogs | Oligodendroglioma | Definitive (MRI and biopsy) | No | Yes | 125 days |
| José-López, R. et al. (2021) [2] | 3 dogs | Oligodendroglioma (high-grade) | Definitive (MRI and biopsy) | Chemotherapy (lomustine and temozolomide) | Yes | 206 days |
| Hicks, J. et al. (2019) [30] | 4 dogs | Gliomas (1 gliomasglioblastoma multiforme and 3 oligodendroglioma) | Definitive (MRI and biopsy) | Intratumoral temozolomide microcylinders | Yes | Not reported |
| Bentley, R. et al. (2018) [28] | 8 dogs | Gliomas (7 oligodendrogliomas and 1 astrocytoma (6 high grade, 2 low grade) | Definitive (MRI and biopsy) | Chlorambucil and lomustine | Yes | 257 days |
| Adams et al. (2005) [27] | 13 dogs | Gliomas | Definitive (MRI and biopsy) | Radiotherapy | Yes | 300 |
| José-López, R. et al. (2021) [2] | 1 dog | Glioma undefined (high-grade) | Definitive (MRI and biopsy) | Radiotherapy | Yes | 94 days |
| Our study | 14 dogs | Gliomas (4 oligodendroglioma, 8 anaplastic oligodendroglioma and 2 glioblastoma grade IV) | Definitive (MRI or CT and biopsy) | Temozolomide and toceranib phosphate, lomustine and/or melphalan | Yes | 240 days |
ST = survival time, MRI = magnetic resonance imaging, CT = computed tomography.